Your browser doesn't support javascript.
loading
A causal roadmap for generating high-quality real-world evidence.
Dang, Lauren E; Gruber, Susan; Lee, Hana; Dahabreh, Issa J; Stuart, Elizabeth A; Williamson, Brian D; Wyss, Richard; Díaz, Iván; Ghosh, Debashis; Kiciman, Emre; Alemayehu, Demissie; Hoffman, Katherine L; Vossen, Carla Y; Huml, Raymond A; Ravn, Henrik; Kvist, Kajsa; Pratley, Richard; Shih, Mei-Chiung; Pennello, Gene; Martin, David; Waddy, Salina P; Barr, Charles E; Akacha, Mouna; Buse, John B; van der Laan, Mark; Petersen, Maya.
Afiliação
  • Dang LE; Department of Biostatistics, University of California, Berkeley, CA, USA.
  • Gruber S; TL Revolution, Cambridge, MA, USA.
  • Lee H; Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Dahabreh IJ; CAUSALab, Department of Epidemiology and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Stuart EA; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Williamson BD; Biostatistics Division, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Wyss R; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Díaz I; Division of Biostatistics, Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.
  • Ghosh D; Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Kiciman E; Microsoft Research, Redmond, WA, USA.
  • Alemayehu D; Global Biometrics and Data Management, Pfizer Inc., New York, NY, USA.
  • Hoffman KL; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  • Vossen CY; Syneos Health Clinical Solutions, Amsterdam, The Netherlands.
  • Huml RA; Syneos Health Clinical Solutions, Morrisville, NC, USA.
  • Ravn H; Novo Nordisk, Søborg, Denmark.
  • Kvist K; Novo Nordisk, Søborg, Denmark.
  • Pratley R; AdventHealth Translational Research Institute, Orlando, FL, USA.
  • Shih MC; Cooperative Studies Program Coordinating Center, VA Palo Alto Health Care System, Palo Alto, CA, USA.
  • Pennello G; Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.
  • Martin D; Division of Imaging Diagnostics and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Waddy SP; Global Real World Evidence Group, Moderna, Cambridge, MA, USA.
  • Barr CE; National Center for Advancing Translational Sciences, Bethesda, MD, USA.
  • Akacha M; Graticule Inc., Newton, MA, USA.
  • Buse JB; Adaptic Health Inc., Palo Alto, CA, USA.
  • van der Laan M; Novartis Pharma AG, Basel, Switzerland.
  • Petersen M; Division of Endocrinology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
J Clin Transl Sci ; 7(1): e212, 2023.
Article em En | MEDLINE | ID: mdl-37900353
ABSTRACT
Increasing emphasis on the use of real-world evidence (RWE) to support clinical policy and regulatory decision-making has led to a proliferation of guidance, advice, and frameworks from regulatory agencies, academia, professional societies, and industry. A broad spectrum of studies use real-world data (RWD) to produce RWE, ranging from randomized trials with outcomes assessed using RWD to fully observational studies. Yet, many proposals for generating RWE lack sufficient detail, and many analyses of RWD suffer from implausible assumptions, other methodological flaws, or inappropriate interpretations. The Causal Roadmap is an explicit, itemized, iterative process that guides investigators to prespecify study design and analysis plans; it addresses a wide range of guidance within a single framework. By supporting the transparent evaluation of causal assumptions and facilitating objective comparisons of design and analysis choices based on prespecified criteria, the Roadmap can help investigators to evaluate the quality of evidence that a given study is likely to produce, specify a study to generate high-quality RWE, and communicate effectively with regulatory agencies and other stakeholders. This paper aims to disseminate and extend the Causal Roadmap framework for use by clinical and translational researchers; three companion papers demonstrate applications of the Causal Roadmap for specific use cases.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Clin Transl Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Clin Transl Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos